SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. L. Nam, E. Villeneuve, E. M. A. Hensor, R. J. Wakefield, P. G. Conaghan, M. J. Green, A. Gough, M. Quinn, R. Reece, S. R. Cox, M. H. Buch, D. M. van der Heijde, P. Emery, A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial, Annals of the Rheumatic Diseases, 2014, 73, 6, 1027

    CrossRef

  2. 2
    Ana Arana-Guajardo, Lorena Pérez-Barbosa, David Vega-Morales, Janett Riega-Torres, Jorge Esquivel-Valerio, Mario Garza-Elizondo, Aplicación de un modelo de predicción de progresión de artritis reumatoide en pacientes con artritis indiferenciada, Reumatología Clínica, 2014,

    CrossRef

  3. 3
    Ana Arana-Guajardo, Lorena Pérez-Barbosa, David Vega-Morales, Janett Riega-Torres, Jorge Esquivel-Valerio, Mario Garza-Elizondo, Application of a Prediction Model for the Progression of Rheumatoid Arthritis in Patients With Undifferentiated Arthritis, Reumatología Clínica (English Edition), 2014,

    CrossRef

  4. 4
    Agata N. Burska, Laura Hunt, Marjorie Boissinot, Rocky Strollo, Brent J. Ryan, Ed Vital, Ahuva Nissim, Paul G. Winyard, Paul Emery, Frederique Ponchel, Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis, Mediators of Inflammation, 2014, 2014, 1

    CrossRef

  5. 5
    Laura Hunt, Paul Emery, Defining populations at risk of rheumatoid arthritis: the first steps to prevention, Nature Reviews Rheumatology, 2014, 10, 9, 521

    CrossRef

  6. 6
    J. van Aken, L. Heimans, H. Gillet-van Dongen, K. Visser, H. K. Ronday, I. Speyer, A. J. Peeters, T. W. J. Huizinga, C. F. Allaart, Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study), Annals of the Rheumatic Diseases, 2014, 73, 2, 396

    CrossRef

  7. 7
    A N Burska, K Roget, M Blits, L Soto Gomez, F van de Loo, L D Hazelwood, C L Verweij, A Rowe, G N Goulielmos, L G M van Baarsen, F Ponchel, Gene expression analysis in RA: towards personalized medicine, The Pharmacogenomics Journal, 2014, 14, 2, 93

    CrossRef

  8. 8
    Anaïs Gardette, Sébastien Ottaviani, Florence Tubach, Carine Roy, Pascale Nicaise-Roland, Elisabeth Palazzo, Ghislaine Gill, Olivier Meyer, Philippe Dieudé, High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis, Joint Bone Spine, 2014,

    CrossRef

  9. 9
    Ning-Sheng Lai, Tzung-Yi Tsai, Chung-Yi Li, Malcolm Koo, Chia-Li Yu, Ming-Chi Lu, Increased Frequency and Costs of Ambulatory Medical Care Utilization Prior to the Diagnosis of Rheumatoid Arthritis: A National Population-Based Study, Arthritis Care & Research, 2014, 66, 3
  10. 10
    Kevin D. Deane, Hani El-Gabalawy, Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE, Nature Reviews Rheumatology, 2014, 10, 4, 212

    CrossRef

  11. 11
    Hirotaka Katada, Naoichiro Yukawa, Hisashi Urushihara, Shiro Tanaka, Tsuneyo Mimori, Koji Kawakami, Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan, Clinical Rheumatology, 2014,

    CrossRef

  12. 12
    Axel Finckh, Kevin D. Deane, Prevention of Rheumatic Diseases, Rheumatic Disease Clinics of North America, 2014,

    CrossRef

  13. 13
    E. Perry, C. Kelly, P. Eggleton, A. De Soyza, D. Hutchinson, The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?, Rheumatology, 2014,

    CrossRef

  14. 14
    R. B. Mueller, M. Schiff, T. Kaegi, A. Finckh, S. R. Haile, H. Schulze-Koops, J. von Kempis, The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis, Clinical Rheumatology, 2014,

    CrossRef

  15. 15
    Marieke Bax, Tom W. J. Huizinga, René E. M. Toes, The pathogenic potential of autoreactive antibodies in rheumatoid arthritis, Seminars in Immunopathology, 2014, 36, 3, 313

    CrossRef

  16. 16
    Ji Young Kim, Soo-Kyung Cho, Minkyung Han, Yun Young Choi, Sang-Cheol Bae, Yoon-Kyoung Sung, The Role of Bone Scintigraphy in the Diagnosis of Rheumatoid Arthritis According to the 2010 ACR/EULAR Classification Criteria, Journal of Korean Medical Science, 2014, 29, 2, 204

    CrossRef

  17. 17
    Sen Hee Tay, Anita Y. N. Lim, Tung Lin Lee, Bernadette P. L. Low, Peter P. Cheung, The value of referral letter information in predicting inflammatory arthritis—factors important for effective triaging, Clinical Rheumatology, 2014, 33, 3, 409

    CrossRef

  18. 18
    Between the Lines of Genetic Code, 2014,

    CrossRef

  19. 19
    Geoffrey Littlejohn, Lynden Roberts, Mark Arnold, Paul Bird, Simon Burnet, Julien Jager, Hedley Griffiths, Dave Nicholls, James Scott, Jane Zochling, Kathleen E. Tymms, A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control, International Journal of Rheumatic Diseases, 2013, 16, 5
  20. 20
    Nicola Bizzaro, Elena Bartoloni, Gabriella Morozzi, Stefania Manganelli, Valeria Riccieri, Paola Sabatini, Matteo Filippini, Marilina Tampoia, Antonella Afeltra, Giandomenico Sebastiani, Claudia Alpini, Vittorio Bini, Onelia Bistoni, Alessia Alunno, Roberto Gerli, Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study, Arthritis Research & Therapy, 2013, 15, 1, R16

    CrossRef

  21. 21
    Elizabeth W. Karlson, Bo Ding, Brendan T. Keenan, Katherine Liao, Karen H. Costenbader, Lars Klareskog, Lars Alfredsson, Lori B. Chibnik, Association of Environmental and Genetic Factors and Gene–Environment Interactions With Risk of Developing Rheumatoid Arthritis, Arthritis Care & Research, 2013, 65, 7
  22. 22
    Marion Le Boëdec, Thierry Marhadour, Valérie Devauchelle-Pensec, Sandrine Jousse-Joulin, Aymeric Binard, Bruno Fautrel, René Marc Flipo, Xavier Le Loët, Jean François Ménard, Alain Saraux, Baseline Laboratory Test Abnormalities are Common in Early Arthritis but Rarely Contraindicate Methotrexate: Study of Three Cohorts (ESPOIR, VErA, and Brittany), Seminars in Arthritis and Rheumatism, 2013, 42, 5, 474

    CrossRef

  23. 23
    Kevin D. Deane, Can rheumatoid arthritis be prevented?, Best Practice & Research Clinical Rheumatology, 2013, 27, 4, 467

    CrossRef

  24. 24
    P. F. Kerkman, Y. Rombouts, E. I. H. van der Voort, L. A. Trouw, T. W. J. Huizinga, R. E. Toes, H. U. Scherer, Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, 2013, 72, 7, 1259

    CrossRef

  25. 25
    K. V. C. Wevers-de Boer, L. Heimans, T. W. J. Huizinga, C. F. Allaart, Drug therapy in undifferentiated arthritis: a systematic literature review, Annals of the Rheumatic Diseases, 2013, 72, 9, 1436

    CrossRef

  26. 26
    William H. Robinson, Tamsin M. Lindstrom, Regina K. Cheung, Jeremy Sokolove, Mechanistic biomarkers for clinical decision making in rheumatic diseases, Nature Reviews Rheumatology, 2013, 9, 5, 267

    CrossRef

  27. 27
    Vasco Romão, Helena Canhão, João Fonseca, Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?, BMC Medicine, 2013, 11, 1, 17

    CrossRef

  28. 28
    Juan Zhao, Guangtao Li, Jing Xu, Xiaohui Zhang, Zhuoli Zhang, Performance des critères de l’American College of Rheumatology/European League Against Rheumatism 2010 dans le diagnostic de la polyarthrite rhumatoïde chez les patients chinois, Revue du Rhumatisme, 2013, 80, 4, 378

    CrossRef

  29. 29
    Juan Zhao, Guangtao Li, Jing Xu, Xiaohui Zhang, Zhuoli Zhang, Performance of the American College of Rheumatology/European League Against Rheumatism 2010 criteria for the diagnosis of rheumatoid arthritis in Chinese patients, Joint Bone Spine, 2013, 80, 5, 482

    CrossRef

  30. 30
    Toshiaki Kogure, Naoyuki Harada, Takeshi Tatsumi, Hiroshi Fujinaga, Persistent undifferentiated arthritis successfully treated with the Japanese herbal medicine “Eppikajutsuto”, European Journal of Integrative Medicine, 2013, 5, 2, 184

    CrossRef

  31. 31
    C. Fiehn, G. Keyßer, H.-M. Lorenz, Personalisierte Medizin in der Auswahl konventioneller Immunsuppressiva und „disease modifying anti-rheumatic drugs“, Zeitschrift für Rheumatologie, 2013, 72, 1, 27

    CrossRef

  32. 32
    Jennifer H. Humphreys, Deborah P.M. Symmons, Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis, Current Opinion in Rheumatology, 2013, 25, 2, 157

    CrossRef

  33. 33
    Anna B Montgomery, Patrick J Venables, Benjamin A Fisher, The case for measuring antibodies to specific citrullinated antigens, Expert Review of Clinical Immunology, 2013, 9, 12, 1185

    CrossRef

  34. 34
    Kazuya Hiura, Sachiko Iwaki-Egawa, Toshiyuki Kawashima, Shin-ichi Fujisawa, Tsuyoshi Takeda, Hitoshi Komori, Yasuhiro Watanabe, The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis, Rheumatology International, 2013, 33, 9, 2309

    CrossRef

  35. 35
    Edith Villeneuve, To screen or not to screen: How to find and identify very early arthritis, Best Practice & Research Clinical Rheumatology, 2013, 27, 4, 487

    CrossRef

  36. 36
    Annette H.M. van der Helm-van Mil, Thomas W.J. Huizinga, Kelley's Textbook of Rheumatology, 2013,

    CrossRef

  37. 37
    James R. O'Dell, Kelley's Textbook of Rheumatology, 2013,

    CrossRef

  38. 38
    Yan Geng, Wei Zhou, Zhuo-li Zhang, A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients, Rheumatology International, 2012, 32, 12, 3897

    CrossRef

  39. 39
    G. H. Kingsley, A. Kowalczyk, H. Taylor, F. Ibrahim, J. C. Packham, N. J. McHugh, D. M. Mulherin, G. D. Kitas, K. Chakravarty, B. D. M. Tom, A. G. O'Keeffe, P. J. Maddison, D. L. Scott, A randomized placebo-controlled trial of methotrexate in psoriatic arthritis, Rheumatology, 2012, 51, 8, 1368

    CrossRef

  40. 40
    I. C. van Eijk, M. M. J. Nielen, I. van der Horst-Bruinsma, G. J. Tijhuis, M. Boers, B. A. C. Dijkmans, D. van Schaardenburg, Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial, Rheumatology, 2012, 51, 4, 686

    CrossRef

  41. 41
    Parawee Suwannalai, Leendert A. Trouw, Rene E. M. Toes, Tom W. J. Huizinga, Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis, Modern Rheumatology, 2012, 22, 1, 15

    CrossRef

  42. 42
    Parawee Suwannalai, Leendert A. Trouw, Rene E. M. Toes, Tom W. J. Huizinga, Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis, Modern Rheumatology, 2012, 22, 1, 15

    CrossRef

  43. 43
    Sarah Horton, Ceara Walsh, Paul Emery, Certolizumab pegol for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 2012, 12, 2, 235

    CrossRef

  44. 44
    L. R. Coulthard, J. Geiler, R. J. Mathews, L. D. Church, L. J. Dickie, D. L. Cooper, C. Wong, S. Savic, D. Bryer, M. H. Buch, P. Emery, A. W. Morgan, M. F. McDermott, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clinical & Experimental Immunology, 2012, 170, 1
  45. 45
    Ignazio Olivieri, Piercarlo Sarzi-Puttini, Serena Bugatti, Fabiola Atzeni, Salvatore d'Angelo, Roberto Caporali, Early treatment in early undifferentiated arthritis, Autoimmunity Reviews, 2012, 11, 8, 589

    CrossRef

  46. 46
    Fereydoun Davatchi, Iraj Salehi Abari, Soosan Soroosh, Mohsen Soroosh, Bahar Sadeghi Abdollahi, Performance of the 2010 rheumatoid arthritis classification criteria, International Journal of Rheumatic Diseases, 2012, 15, 5
  47. 47
    Suzanne MM Verstappen, Sally-Anne Owen, Kimme L Hyrich, Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis, International Journal of Clinical Rheumatology, 2012, 7, 5, 559

    CrossRef

  48. 48
    You Jung Ha, Yong-Beom Park, Myoung-Kyun Son, Sang-Youn Jung, Kwang-Hoon Lee, Soo-Kon Lee, Predictive factors related to progression toward rheumatoid arthritis in Korean patients with undifferentiated arthritis, Rheumatology International, 2012, 32, 6, 1555

    CrossRef

  49. 49
    Karima Benbouazza, Hanan Rkain, Bahia Benchekroun, Bouchra Amine, Fatiha Bzami, Leila Benbrahim, Ouafa Atouf, Malika Essakalli, Redouane Abouqal, Maxime Dougados, Najia Hajjaj-Hassouni, Remission in early rheumatoid arthritis treated with conventional DMARDs. Results of a two-year follow-up study of El Ayachi Moroccan cohort, Joint Bone Spine, 2012, 79, 1, 43

    CrossRef

  50. 50
    K. Krüger, J. Wollenhaupt, K. Albrecht, R. Alten, M. Backhaus, C. Baerwald, W. Bolten, J. Braun, H. Burkhardt, G. Burmester, M. Gaubitz, A. Gause, E. Gromnica-Ihle, H. Kellner, J. Kuipers, A. Krause, H.-M. Lorenz, B. Manger, H. Nüßlein, H.-G. Pott, A. Rubbert-Roth, M. Schneider, C. Specker, H. Schulze-Koops, H.-P. Tony, S. Wassenberg, U. Müller-Ladner, S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2012, Zeitschrift für Rheumatologie, 2012, 71, 7, 592

    CrossRef

  51. 51
    Marc R. Kok, Paul P. Tak, Taking advances from bench to bedside during the last decade, Best Practice & Research Clinical Rheumatology, 2012, 26, 2, 225

    CrossRef

  52. 52
    Annemiek Willemze, Leendert A. Trouw, René E. M. Toes, Tom W. J. Huizinga, The influence of ACPA status and characteristics on the course of RA, Nature Reviews Rheumatology, 2012, 8, 3, 144

    CrossRef

  53. 53
    Deepali Sen, Richard Brasington, Tight Disease Control in Early RA, Rheumatic Disease Clinics of North America, 2012, 38, 2, 327

    CrossRef

  54. 54
    P. H. P. de Jong, J. M. W. Hazes, D. van Zeben, P. A. van der Lubbe, M. H. de Jager, P. B. de Sonnaville, J. J. Luime, A. E. A. M. Weel, Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria, Rheumatology, 2012, 51, 7, 1269

    CrossRef

  55. 55
    Junko Kita, Mami Tamai, Kazuhiko Arima, Yoshikazu Nakashima, Takahisa Suzuki, Shin-ya Kawashiri, Naoki Iwamoto, Akitomo Okada, Tomohiro Koga, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Hiroaki Ida, Kiyoshi Aoyagi, Masataka Uetani, Katsumi Eguchi, Atsushi Kawakami, Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration, Modern Rheumatology, 2012, 22, 3, 346

    CrossRef

  56. 56
    Junko Kita, Mami Tamai, Kazuhiko Arima, Yoshikazu Nakashima, Takahisa Suzuki, Shin-ya Kawashiri, Naoki Iwamoto, Akitomo Okada, Tomohiro Koga, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Hiroaki Ida, Kiyoshi Aoyagi, Masataka Uetani, Katsumi Eguchi, Atsushi Kawakami, Treatment discontinuation in patients with very early rheumatoid arthritis in sustained simplified disease activity index remission after synthetic disease-modifying anti-rheumatic drug administration, Modern Rheumatology, 2012, 22, 3, 346

    CrossRef

  57. 57
    Kevin Pile, Treatment of early undifferentiated arthritis, Indian Journal of Rheumatology, 2012, 7, 4, 215

    CrossRef

  58. 58
    M. Kristen Demoruelle, Kevin D. Deane, Treatment Strategies in Early Rheumatoid Arthritis and Prevention of Rheumatoid Arthritis, Current Rheumatology Reports, 2012, 14, 5, 472

    CrossRef

  59. 59
    Fabiola Atzeni, Piercarlo Sarzi-Puttini, Twelve years’ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice, Expert Review of Clinical Immunology, 2012, 8, 3, 213

    CrossRef

  60. 60
    Peter Taylor, Juliane Gartemann, Jeanie Hsieh, James Creeden, A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis, Autoimmune Diseases, 2011, 2011, 1

    CrossRef

  61. 61
    Hans Ulrich Scherer, Gerd-Rüdiger Burmester, Adaptive immunity in rheumatic diseases – Bystander or pathogenic player?, Best Practice & Research Clinical Rheumatology, 2011, 25, 6, 785

    CrossRef

  62. 62
    Walther J. van Venrooij, Joyce J. B. C. van Beers, Ger J. M. Pruijn, Anti-CCP antibodies: the past, the present and the future, Nature Reviews Rheumatology, 2011, 7, 7, 391

    CrossRef

  63. 63
    M. Kristen Demoruelle, Kevin Deane, Antibodies to Citrullinated Protein Antigens (ACPAs): Clinical and Pathophysiologic Significance, Current Rheumatology Reports, 2011, 13, 5, 421

    CrossRef

  64. 64
    J. Shi, R. Knevel, P. Suwannalai, M. P. van der Linden, G. M. C. Janssen, P. A. van Veelen, N. E. W. Levarht, A. H. M. van der Helm-van Mil, A. Cerami, T. W. J. Huizinga, R. E. M. Toes, L. A. Trouw, Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage, Proceedings of the National Academy of Sciences, 2011, 108, 42, 17372

    CrossRef

  65. 65
    Gert Jan van der Wilt, Hans Groenewoud, Piet van Riel, Bridging the gap between aggregate data and individual patient management: A Bayesian approach, International Journal of Technology Assessment in Health Care, 2011, 27, 02, 133

    CrossRef

  66. 66
    Annette H. M. van der Helm-van Mil, Clinical guidelines: Classifying RA the 2010 way—what does it mean for the clinic?, Nature Reviews Rheumatology, 2011, 7, 1, 9

    CrossRef

  67. 67
    Philip C Robinson, William J Taylor, Decreasing time to treatment in rheumatoid arthritis: review of delays in presentation, referral and assessment, International Journal of Clinical Rheumatology, 2011, 6, 2, 173

    CrossRef

  68. 68
    J. Marcos, C. Waimann, F. Dal Pra, J. Hogrefe, S. Retamozo, F. Caeiro, L. Casalla, M. Benegas, O. Rillo, A. Spindler, H. Berman, A. Berman, A. Secco, R. Garcia Salinas, A. Catalan Pellet, F. Ceccato, S. Paira, J. C. Marcos, J. A. Maldonado Cocco, G. Citera, General characteristics of an early arthritis cohort in Argentina, Rheumatology, 2011, 50, 1, 110

    CrossRef

  69. 69
    Philippe Dieudé, Henri-Jean Garchon, Les applications en rhumatologie: en génomique, Revue du Rhumatisme, 2011, 78, S178

    CrossRef

  70. 70
    Klaartje Somers, Piet Geusens, Dirk Elewaut, Filip De Keyser, Jean-Luc Rummens, Marieke Coenen, Marlies Blom, Piet Stinissen, Veerle Somers, Novel autoantibody markers for early and seronegative rheumatoid arthritis, Journal of Autoimmunity, 2011, 36, 1, 33

    CrossRef

  71. 71
    Saedis Saevarsdottir, Sara Wedrén, Maria Seddighzadeh, Camilla Bengtsson, Annmarie Wesley, Staffan Lindblad, Johan Askling, Lars Alfredsson, Lars Klareskog, Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts, Arthritis & Rheumatism, 2011, 63, 1
  72. 72
    I.C. Scott, S. Steer, C.M. Lewis, A.P. Cope, Precipitating and perpetuating factors of rheumatoid arthritis immunopathology – linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis, Best Practice & Research Clinical Rheumatology, 2011, 25, 4, 447

    CrossRef

  73. 73
    D. P. C. de Rooy, M. P. M. van der Linden, R. Knevel, T. W. J. Huizinga, A. H. M. van der Helm-van Mil, Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic?, Rheumatology, 2011, 50, 1, 93

    CrossRef

  74. 74
    Josef S. Smolen, Maarten Boers, Eric C. Abadie, Ferdinand C. Breedveld, Paul Emery, Thomas Bardin, Niti Goel, Dominique J. Ethgen, Bernard P. Avouac, Willard H. Dere, Patrick Durez, Marco Matucci-Cerinic, Bruno Flamion, Andrea Laslop, Frits J. Lekkerkerker, Pierre Miossec, Bruce H. Mitlak, Sif Ormarsdóttir, Laurence Paolozzi, Ravi Rao, Susan Reiter, Yannis Tsouderos, Jean-Yves Reginster, Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA, Current Medical Research and Opinion, 2011, 27, 2, 315

    CrossRef

  75. 75
    Karima Benbouazza, Hanan Rkain, Bahia Benchekroun, Bouchra Amine, Fatiha Bzami, Leila Benbrahim, Ouafa Atouf, Malika Essakalli, Redouane Abouqal, Maxime Dougados, Najia Hajjaj-Hassouni, Rémission dans la polyarthrite rhumatoïde précoce sous traitements des fonds conventionnels. Résultats à deux ans de suivi de la cohorte marocaine El Ayachi, Revue du Rhumatisme, 2011, 78, 6, 525

    CrossRef

  76. 76
    Benazir Saleem, Ceara AE Walsh, Paul Emery, Remission in inflammatory arthritis: a new immunological target, Immunotherapy, 2011, 3, 4, 459

    CrossRef

  77. 77
    Nina A. Daha, Rene E. M. Toes, Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease?, Nature Reviews Rheumatology, 2011, 7, 4, 202

    CrossRef

  78. 78
    Joaquim Polido-Pereira, Elsa Vieira-Sousa, João Eurico Fonseca, Rheumatoid arthritis: What is refractory disease and how to manage it?, Autoimmunity Reviews, 2011, 10, 11, 707

    CrossRef

  79. 79
    Lars Klareskog, Vivianne Malmström, Karin Lundberg, Leonid Padyukov, Lars Alfredsson, Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis, Seminars in Immunology, 2011, 23, 2, 92

    CrossRef

  80. 80
    Vivian P Bykerk, Strategies to prevent rheumatoid arthritis in high-risk patients, Current Opinion in Rheumatology, 2011, 1

    CrossRef

  81. 81
    Johanna M. W. Hazes, Jolanda J. Luime, The epidemiology of early inflammatory arthritis, Nature Reviews Rheumatology, 2011, 7, 7, 381

    CrossRef

  82. 82
    V Rantalaiho, H Kautiainen, L Virta, M Korpela, T Möttönen, K Puolakka, Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000–2007, Scandinavian Journal of Rheumatology, 2011, 40, 1, 16

    CrossRef

  83. 83
    Ronald F. van Vollenhoven, Unresolved issues in biologic therapy for rheumatoid arthritis, Nature Reviews Rheumatology, 2011, 7, 4, 205

    CrossRef

  84. 84
    L. A. Trouw, T. W. J. Huizinga, Which elements of the criteria for RA are stable over time?, Rheumatology, 2011, 50, 2, 248

    CrossRef

  85. 85
    Yusuf Yazici, Rheumatology, 2011,

    CrossRef

  86. 86
    Daniel Aletaha, Tuhina Neogi, Alan J. Silman, Julia Funovits, David T. Felson, Clifton O. Bingham, Neal S. Birnbaum, Gerd R. Burmester, Vivian P. Bykerk, Marc D. Cohen, Bernard Combe, Karen H. Costenbader, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Johanna M. W. Hazes, Kathryn Hobbs, Tom W. J. Huizinga, Arthur Kavanaugh, Jonathan Kay, Tore K. Kvien, Timothy Laing, Philip Mease, Henri A. Ménard, Larry W. Moreland, Raymond L. Naden, Theodore Pincus, Josef S. Smolen, Ewa Stanislawska-Biernat, Deborah Symmons, Paul P. Tak, Katherine S. Upchurch, Jiří Vencovský, Frederick Wolfe, Gillian Hawker, 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis & Rheumatism, 2010, 62, 9
  87. You have free access to this content87
    Richard C. Chou, Martin C. Mihm, John H. Stone, A 44-year-old woman with right ankle pain, Arthritis Care & Research, 2010, 62, 11
  88. 88
    P Ghosh, PS Karmakar, PS Mahapatra, SK Dhar, A Ghosh, A prospective study for outcome and prediction of early arthritis: a tertiary care centre observation, Indian Journal of Rheumatology, 2010, 5, 3, 106

    CrossRef

  89. 89
    James R. O'Dell, Challenges in clinical trial design in inflammatory arthritis, Best Practice & Research Clinical Rheumatology, 2010, 24, 4, 457

    CrossRef

  90. 90
    Huseyin TE Ozer, Zeynep Ozbalkan, Clinical efficacy of TNF-α inhibitors: an update, International Journal of Clinical Rheumatology, 2010, 5, 1, 101

    CrossRef

  91. 91
    Karin Hellgren, Karin E. Smedby, Nils Feltelius, Eva Baecklund, Johan Askling, Do rheumatoid arthritis and lymphoma share risk factors?: A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis, Arthritis & Rheumatism, 2010, 62, 5
  92. 92
    Maria Seddighzadeh, Marina Korotkova, Henrik Källberg, Bo Ding, Nina Daha, Fina A S Kurreeman, Rene E M Toes, Tom W Huizinga, Anca I Catrina, Lars Alfredsson, Lars Klareskog, Leonid Padyukov, Evidence for interaction between 5-hydroxytryptamine (serotonin) receptor 2A and MHC type II molecules in the development of rheumatoid arthritis, European Journal of Human Genetics, 2010, 18, 7, 821

    CrossRef

  93. 93
    L. G. Schipper, L. T. C. van Hulst, R. Grol, P. L. C. M. van Riel, M. E. J. L. Hulscher, J. Fransen, Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome, Rheumatology, 2010, 49, 11, 2154

    CrossRef

  94. 94
    Hans U Scherer, Thomas Dörner, Gerd R Burmester, Patient-tailored therapy in rheumatoid arthritis: an editorial review, Current Opinion in Rheumatology, 2010, 22, 3, 237

    CrossRef

  95. 95
    Kevin D. Deane, Jill M. Norris, V. Michael Holers, Preclinical Rheumatoid Arthritis: Identification, Evaluation, and Future Directions for Investigation, Rheumatic Disease Clinics of North America, 2010, 36, 2, 213

    CrossRef

  96. 96
    Klaus P. Machold, Prevention and cure of rheumatoid arthritis: Is it possible?, Best Practice & Research Clinical Rheumatology, 2010, 24, 3, 353

    CrossRef

  97. 97
    David L Scott, Frederick Wolfe, Tom WJ Huizinga, Rheumatoid arthritis, The Lancet, 2010, 376, 9746, 1094

    CrossRef

  98. 98
    K Puolakka, H Kautiainen, T Pohjolainen, L Virta, Rheumatoid arthritis (RA) remains a threat to work productivity: a nationwide register-based incidence study from Finland, Scandinavian Journal of Rheumatology, 2010, 39, 5, 436

    CrossRef

  99. 99
    Ashok Kumar, Rheumatoid arthritis: let us nip the evil in the bud!, Indian Journal of Rheumatology, 2010, 5, 3, 103

    CrossRef

  100. 100
    John D. Isaacs, The changing face of rheumatoid arthritis: sustained remission for all?, Nature Reviews Immunology, 2010, 10, 8, 605

    CrossRef

  101. 101
    S. L. Westlake, A. N. Colebatch, J. Baird, P. Kiely, M. Quinn, E. Choy, A. J. K. Ostor, C. J. Edwards, The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review, Rheumatology, 2010, 49, 2, 295

    CrossRef

  102. 102
    Veena K Ranganath, Sogol Amjadi, Edmond Melikterminas, Daniel E Furst, The older rheumatoid arthritis patients: who are they and how should they be treated?, Aging Health, 2010, 6, 5, 533

    CrossRef

  103. 103
    Faye A.H. Cooles, John D. Isaacs, Treating to re-establish tolerance in inflammatory arthritis – lessons from other diseases, Best Practice & Research Clinical Rheumatology, 2010, 24, 4, 497

    CrossRef

  104. 104
    Jaap Fransen, Karen Visser, Henrike van Dongen, Tom Huizinga, Piet L. C. M. van Riel, Désirée M. van der Heijde, Validity of the disease activity score in undifferentiated arthritis, Arthritis Care & Research, 2010, 62, 10
  105. 105
    Hayley Mainman, Emma McClaren, Carol Heycock, Vadivelu Saravanan, Jennifer Hamilton, Clive Kelly, When should we use parenteral methotrexate?, Clinical Rheumatology, 2010, 29, 10, 1093

    CrossRef

  106. 106
    Hans Ulrich Scherer, Gerd R. Burmester, A clinical perspective of rheumatoid arthritis, European Journal of Immunology, 2009, 39, 8
  107. 107
    Juergen Braun, Rolf Rau, An update on methotrexate, Current Opinion in Rheumatology, 2009, 21, 3, 216

    CrossRef

  108. 108
    U. Bergstrom, L. T. H. Jacobsson, C. Turesson, Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden, Rheumatology, 2009, 48, 12, 1600

    CrossRef

  109. 109
    Dirkjan van Schaardenburg, Ben A. C. Dijkmans, Clinical approaches to early inflammatory arthritis, Nature Reviews Rheumatology, 2009, 5, 11, 627

    CrossRef

  110. 110
    D. McGonagle, A. L. Tan, Comment on: The use of MRI in early RA, Rheumatology, 2009, 48, 4, 450

    CrossRef

  111. 111
    P. D. W. Kiely, A. K. Brown, C. J. Edwards, D. T. O'Reilly, A. J. K. Ostor, M. Quinn, A. Taggart, P. C. Taylor, R. J. Wakefield, P. G. Conaghan, Contemporary treatment principles for early rheumatoid arthritis: a consensus statement, Rheumatology, 2009, 48, 7, 765

    CrossRef

  112. 112
    Arthur G. Pratt, John D. Isaacs, Derek L. Mattey, Current concepts in the pathogenesis of early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 2009, 23, 1, 37

    CrossRef

  113. 113
    Tuulikki Sokka, Heidi Mäkinen, Drug management of early rheumatoid arthritis – 2008, Best Practice & Research Clinical Rheumatology, 2009, 23, 1, 93

    CrossRef

  114. 114
    Axel Finckh, Early inflammatory arthritis versus rheumatoid arthritis, Current Opinion in Rheumatology, 2009, 21, 2, 118

    CrossRef

  115. 115
    C. Fiehn, Methotrexat in der Rheumatologie, Zeitschrift für Rheumatologie, 2009, 68, 9, 747

    CrossRef

  116. 116
    Lars Klareskog, Sara Wedrén, Lars Alfredsson, On the origins of complex immune-mediated disease: the example of rheumatoid arthritis, Journal of Molecular Medicine, 2009, 87, 4, 357

    CrossRef

  117. 117
    Francisco Javier Narváez García, Qué, cómo, cuándo y hasta cuándo tratar una artritis indiferenciada, Reumatología Clínica, 2009, 5, 31

    CrossRef

  118. 118
    Lars Klareskog, Anca Irinel Catrina, Stephen Paget, Rheumatoid arthritis, The Lancet, 2009, 373, 9664, 659

    CrossRef

  119. 119
    Daniel Aletaha, T.W.J. Huizinga, The use of data from early arthritis clinics for clinical research, Best Practice & Research Clinical Rheumatology, 2009, 23, 1, 117

    CrossRef

  120. 120
    Hae-Rim Kim, Chong-Hyun Yoon, Ultrasonographic Assessment in Rheumatoid Arthritis, The Journal of the Korean Rheumatism Association, 2009, 16, 2, 74

    CrossRef

  121. 121
    Tom W.J. Huizinga, Ferdinand C. Breedveld, Rheumatoid Arthritis, 2009,

    CrossRef

  122. 122
    Walther J. Van Venrooij, Joyce J.B.C. Van Beers, Ger J.M. Pruijn, Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis, Annals of the New York Academy of Sciences, 2008, 1143, 1
  123. 123
    Lars Klareskog, Mona Widhe, Monika Hermansson, Johan Rönnelid, Antibodies to citrullinated proteins in arthritis: pathology and promise, Current Opinion in Rheumatology, 2008, 20, 3, 300

    CrossRef

  124. 124
    Lyudmila Sizova, Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs, British Journal of Clinical Pharmacology, 2008, 66, 2
  125. 125
    Hernan Castro-Rueda, Arthur Kavanaugh, Biologic therapy for early rheumatoid arthritis: the latest evidence, Current Opinion in Internal Medicine, 2008, 7, 4, 415

    CrossRef

  126. 126
    Hernan Castro-Rueda, Arthur Kavanaugh, Biologic therapy for early rheumatoid arthritis: the latest evidence, Current Opinion in Rheumatology, 2008, 20, 3, 314

    CrossRef

  127. 127
    J. Braun, P. Kästner, P. Flaxenberg, J. Währisch, P. Hanke, W. Demary, U. von Hinüber, K. Rockwitz, W. Heitz, U. Pichlmeier, C. Guimbal-Schmolck, A. Brandt, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis & Rheumatism, 2008, 58, 1
  128. 128
    Michael H Weisman, Do all drugs and treatments for rheumatoid arthritis have the same efficacy?, Nature Clinical Practice Rheumatology, 2008, 4, 6, 298

    CrossRef

  129. 129
    Jeremy Sugarman, Clifton O Bingham, Ethical issues in rheumatology clinical trials, Nature Clinical Practice Rheumatology, 2008,

    CrossRef

  130. 130
    Andrew Hwang, Samardeep Gupta, Matthew H Liang, Identification of people with very early RA for optimal care: a public health challenge, Nature Clinical Practice Rheumatology, 2008, 4, 3, 114

    CrossRef

  131. 131
    Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, Lars Alfredsson, Immunity to Citrullinated Proteins in Rheumatoid Arthritis, Annual Review of Immunology, 2008, 26, 1, 651

    CrossRef

  132. 132
    Sjoerd M van der Kooij, Cornelia F Allaart, Ben AC Dijkmans, Ferdinand C Breedveld, Innovative treatment strategies for patients with rheumatoid arthritis, Current Opinion in Rheumatology, 2008, 20, 3, 287

    CrossRef

  133. 133
    Jackie Nam, Edith Villeneuve, Paul Emery, Predicting the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis, Future Rheumatology, 2008, 3, 5, 441

    CrossRef

  134. 134
    N. Leuchten, M. Aringer, Rheumatoide Arthritis/chronische Polyarthritis heute, Der Internist, 2008, 49, 12, 1471

    CrossRef

  135. 135
    Angus B. Worthing, Thomas R. Cupps, The Rheumatic Causes of Elbow Instability, Hand Clinics, 2008, 24, 1, 79

    CrossRef

  136. 136
    Tuulikki Sokka, Minja Envalds, Theodore Pincus, Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs, Modern Rheumatology, 2008, 18, 3, 228

    CrossRef

  137. 137
    Tuulikki Sokka, Minja Envalds, Theodore Pincus, Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs, Modern Rheumatology, 2008, 18, 3, 228

    CrossRef

  138. 138
    Annette H. M. van Der Helm-van Mil, Jacqueline Detert, Saskia Le Cessie, Andrew Filer, Hans Bastian, Gerd R. Burmester, Tom W. J. Huizinga, Karim Raza, Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making, Arthritis & Rheumatism, 2008, 58, 8
  139. 139
    Joel M Kremer, Does DMARD treatment slow or prevent development of RA in patients with UA?, Nature Clinical Practice Rheumatology, 2007, 3, 12, 690

    CrossRef

  140. 140
    P. L. B. Bruijnzeel, Effect van behandeling met methotrexaat van patiënten die verdacht worden van reumatoïde artritis, Medisch-Farmaceutische Mededelingen, 2007, 45, 9, 276

    CrossRef

  141. 141
    Peter C Taylor, The future of TNF-α antagonism, Future Rheumatology, 2007, 2, 3, 233

    CrossRef

  142. 142
    Christina Trollmo, Lars Klareskog, Predicting and Assessing an Inflammatory Disease and Its Complications: Example from Rheumatoid Arthritis, Pharmaceutical Sciences Encyclopedia,